These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 23065600)

  • 1. Practical guidelines for dose individualization of anticancer targeted drugs.
    Sáez MI; Quero C; Trigo JM; Muros B; Alba E
    Clin Transl Oncol; 2012 Nov; 14(11):812-9. PubMed ID: 23065600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets.
    Yu H; Steeghs N; Nijenhuis CM; Schellens JH; Beijnen JH; Huitema AD
    Clin Pharmacokinet; 2014 Apr; 53(4):305-25. PubMed ID: 24566736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of individualized dosing in oncology: are we there yet?].
    Joerger M
    Praxis (Bern 1994); 2013 Dec; 103(1):33-9. PubMed ID: 24393821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy individualization.
    Veal GJ; Coulthard SA; Boddy AV
    Invest New Drugs; 2003 May; 21(2):149-56. PubMed ID: 12889736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moving towards dose individualization of tyrosine kinase inhibitors.
    Klümpen HJ; Samer CF; Mathijssen RH; Schellens JH; Gurney H
    Cancer Treat Rev; 2011 Jun; 37(4):251-60. PubMed ID: 20833478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose calculation of anticancer drugs.
    Gao B; Klumpen HJ; Gurney H
    Expert Opin Drug Metab Toxicol; 2008 Oct; 4(10):1307-19. PubMed ID: 18798700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment.
    Krens SD; Lassche G; Jansman FGA; Desar IME; Lankheet NAG; Burger DM; van Herpen CML; van Erp NP
    Lancet Oncol; 2019 Apr; 20(4):e200-e207. PubMed ID: 30942181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical treatment guide for dose individualisation in cancer chemotherapy.
    Canal P; Chatelut E; Guichard S
    Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical toxicity of anticancer drugs and its prediction.
    Creaven PJ; Mihich E
    Semin Oncol; 1977 Jun; 4(2):147-63. PubMed ID: 406677
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic drug monitoring of targeted anticancer therapy.
    Decosterd LA; Widmer N; Zaman K; Cardoso E; Buclin T; Csajka C
    Biomark Med; 2015; 9(9):887-93. PubMed ID: 26333311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function.
    Kintzel PE; Dorr RT
    Cancer Treat Rev; 1995 Jan; 21(1):33-64. PubMed ID: 7859226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug dosing in cancer patients with decreased kidney function: A practical approach.
    Sprangers B; Sandhu G; Rosner MH; Tesarova P; Stadler WM; Malyszko J
    Cancer Treat Rev; 2021 Feb; 93():102139. PubMed ID: 33370636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.
    Prasad V; Massey PR; Fojo T
    J Clin Oncol; 2014 May; 32(15):1620-9. PubMed ID: 24711558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining the optimal dose in the development of anticancer agents.
    Mathijssen RH; Sparreboom A; Verweij J
    Nat Rev Clin Oncol; 2014 May; 11(5):272-81. PubMed ID: 24663127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring for dose individualization of Cisplatin in testicular cancer patients based upon total platinum measurement in plasma.
    Salas S; Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Tranchand B; Monjanel-Mouterde S; Baciuchka-Palmaro M; Dupuis C; Yang C; Balti M; Lacarelle B; Duffaud F; Durand A; Favre R
    Ther Drug Monit; 2006 Aug; 28(4):532-9. PubMed ID: 16885721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid dysfunction as an unintended side effect of anticancer drugs.
    Torino F; Barnabei A; Paragliola R; Baldelli R; Appetecchia M; Corsello SM
    Thyroid; 2013 Nov; 23(11):1345-66. PubMed ID: 23750887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
    Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
    Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted cancer. These "smart weapons" hit cancer in novel ways.
    Held-Warmkessel J
    Nursing; 2008 Sep; 38(9):26-32. PubMed ID: 18719487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.